Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1578 EUR
−57.15 M EUR
5.47 M EUR
287.13 M
About Ocugen, Inc.
Sector
CEO
Shankar Musunuri
Headquarters
Malvern
Website
Founded
2013
FIGI
BBG007PQLLW4
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange OCUGEN INC. DL-,001 stocks are traded under the ticker 2H51.
We've gathered analysts' opinions on OCUGEN INC. DL-,001 future price: according to them, 2H51 price has a max estimate of 7.41 EUR and a min estimate of 3.70 EUR. Watch 2H51 chart and read a more detailed OCUGEN INC. DL-,001 stock forecast: see what analysts think of OCUGEN INC. DL-,001 and suggest that you do with its stocks.
2H51 reached its all-time high on Nov 3, 2021 with the price of 15.8750 EUR, and its all-time low was 0.1620 EUR and was reached on Jul 14, 2020. View more price dynamics on 2H51 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track OCUGEN INC. DL-,001 financials in yearly and quarterly reports right on TradingView.
OCUGEN INC. DL-,001 is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
2H51 earnings for the last quarter are −0.04 EUR per share, whereas the estimation was −0.05 EUR resulting in a 9.09% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about OCUGEN INC. DL-,001 earnings.
OCUGEN INC. DL-,001 revenue for the last quarter amounts to 1.02 M EUR, despite the estimated figure of 359.26 K EUR. In the next quarter, revenue is expected to reach 384.50 K EUR.
2H51 net income for the last quarter is −11.65 M EUR, while the quarter before that showed −14.27 M EUR of net income which accounts for 18.34% change. Track more OCUGEN INC. DL-,001 financial stats to get the full picture.
No, 2H51 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2024, the company has 65.00 employees. See our rating of the largest employees — is OCUGEN INC. DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OCUGEN INC. DL-,001 EBITDA is −45.71 M EUR, and current EBITDA margin is −1.07 K%. See more stats in OCUGEN INC. DL-,001 financial statements.
Like other stocks, 2H51 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OCUGEN INC. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.